TASK ORDER 07 (75N95022F00001) FOR IDIQ HHSN271201800024I WITH EUROFINS PANLABS DISCOVERY SERVICES

任务订单 07 (75N95022F00001) 适用于 IDIQ HHSN271201800024I 以及 EUROFINS PANLABS 发现服务

• 批准号: 10721002
• 负责人: JACOB BODE
• 金额: $ 22.43万
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-21 至 2023-09-20
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10721002
• 关键词: Binding; Biological; Biological Assay; Contracts; Disease; Drug Addiction; In Vitro; Ligands; Medical; National Institute of Drug Abuse; Pharmaceutical Preparations; Services; Site; Specific qualifier value; Therapeutic; Toxicology; addiction; biological systems; follow-up; novel; pre-clinical; programs; receptor; receptor binding

The objective of this acquisition is to continue a major component of the National Institute on Drug Abuse’s (NIDA) established contracts, the NIDA/Division of Therapeutics and Medical Consequences (DTMC)/Addiction Treatment Discovery Program (ATDP). The program requires in-house capability to perform in vitro receptor binding assays on a wide variety of receptor targets, and perform follow-up binding and functional assays using appropriate in vitro biological systems, in addition to in vitro predictive toxicology assays.

此次收购的目的是继续作为国家药物滥用研究所(NIDA)既定合同的一个主要组成部分，即NIDA/治疗和医疗后果司(DTMC)/成瘾治疗发现计划(ATDP)。该计划需要内部能力对各种受体靶标进行体外受体结合分析，并使用适当的体外生物系统进行后续结合和功能分析，以及体外预测毒理学分析。